Reduction of Vancomycin-Associated Acute Kidney Injury With Montelukast.

ABSTRACT:

Background

Vancomycin ranks among the most utilized antimicrobial agents in the treatment of serious β-lactam-resistant gram-positive infections, but its use has been associated with nephrotoxicity. Reduction of acute kidney injury (AKI) has been reported in preclinical models with adjuvant montelukast. The purpose of the study was to ascertain if montelukast was associated with a reduction in the prevalence of vancomycin-associated AKI.

Methods

This retrospective cohort study examined adult patients who received intravenous vancomycin between January 2020 and January 2024. The RIFLE criteria (risk, injury, failure, loss, and end-stage kidney disease) were employed in identifying cases of AKI. Additionally, a preclinical vancomycin-associated nephrotoxicity model was establi

SUBMITTER: Teran NS 

PROVIDER: S-EPMC12308645 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature